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Radiation therapy dose
escalation is predicted to
improve local tumor control
in esophageal cancer; how-
ever, any increase in acute
hematologic toxicity could
limit the predicted improve-
ment in patient outcomes.
We investigated the bone
marrow dose of volumetric
modulated arc therapy
(VMAT), proton therapy, and
bone marrow-sparing VMAT
plans for esophageal tumors.
Improved bone marrow
sparing was possible with
VMAT, but only proton
therapy resulted in signifi-
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http://dx.doi.org/10.1016/j.ijrobp.2017.07.025Purpose: Radiation therapy dose escalation using a simultaneous integrated boost
(SIB) is predicted to improve local tumor control in esophageal cancer; however,
any increase in acute hematologic toxicity (HT) could limit the predicted improvement
in patient outcomes. Proton therapy has been shown to significantly reduce HT in lung
cancer patients receiving concurrent chemotherapy. Therefore, we investigated the po-
tential of bone marrow sparing with protons for esophageal tumors.
Methods and Materials: Twenty-one patients with mid-esophageal cancer who had
undergone conformal radiation therapy (3D50) were selected. Two surrogates for bone
marrow were created by outlining the thoracic bones (bone) and only the body of the
thoracic vertebrae (TV) in Eclipse. The percentage of overlap of the TV with the plan-
ning treatment volume was recorded for each patient. Additional plans were created
retrospectively, including a volumetric modulated arc therapy (VMAT) plan with
the same dose as for 3D50; a VMAT SIB plan with a dose prescription of 62.5 Gy
to the high-risk subregion within the planning treatment volume; a reoptimized TV-
sparing VMAT plan; and a proton therapy plan with the same SIB dose prescription.
The bone and TV dose metrics were recorded and compared across all plans and var-
iations with respect to PTV and percentage of overlap for each patient.
Results: The 3D50 plans showed the highest bone mean dose and TV percentage of vol-
ume receiving30Gy (V30Gy) for each patient. TheVMATplans irradiated a larger bone
V10Gy than did the 3D50 plans. The reoptimized VMAT62.5 VT plans showed improvedD, Cancer Research UK/
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cially for patients with larger
planning target volumes.sparing of the TV volume, but only the proton plans showed significant sparing for bone
V10Gy and bone mean dose, especially for patients with a larger PTV.
Conclusions: The results of the present study have shown that proton therapy can
reduced bone marrow toxicity.  2017 The Authors. Published by Elsevier Inc. This
is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).Introduction
Esophageal cancer is the sixth most common cause of death
worldwide, representing 5% of total cancer deaths in 2012
(1). Although surgery offers the best outcomes for patients
with esophageal cancer, only 10% to 20% of patients with
nonmetastatic disease will be eligible for surgical treat-
ment. Therefore, definitive concurrent chemoradiation
therapy has been recognized as a valuable treatment option
for many patients. Also, the recent SCOPE1 trial (ISRCTN
number 47718479) reported good outcomes in the standard
definitive concurrent chemoradiation therapy arm
(cisplatin/5-fluorouracil [5-FU] with 50 Gy in 25 fractions)
with a 2-year overall survival rate of 56%, with hemato-
logic toxicity (HT) grade 3 the most commonly reported
acute side effect (28% of patients) (2). Only 53% of the
patients completed chemotherapy at the full dose (2). Ra-
diation therapy dose escalation using a simultaneous inte-
grated boost (SIB) is predicted to further improve local
tumor control in these patients (3). Treatment planning
studies for patients with mid-esophageal cancer suggested
that a boost dose of 62.5 Gy in 25 fractions could be ach-
ieved using either photons (4) or protons (5) without
exceeding the dose constraints for the heart, spinal cord,
and lungs. A pilot study treating 25 patients with photons
has described safe escalation of 62.5 Gy in 25 fractions as a
boost to a positron emission tomography (PET)-guided
gross tumor volume (GTV) (6). In contrast, any increase in
the radiation dose could cause an increase in HT owing to
greater bone marrow irradiation. This could reduce the
treatment intensity by interrupting delivery or reducing the
dose of concurrent chemotherapy, limiting any predicted
improvement in patient outcomes.
Studies of patients who underwent fractionated radiation
therapy have indicated that at less than w50 Gy, bone
marrow has a large capacity for repair and regeneration
(although this could require many months or even years)
(7). The findings from longitudinal 18F-fluorothymidine
(FLT)-PET imaging of pelvic cancer patients have sug-
gested that acute HT can occur at low doses (4 Gy), with
bone exposed to >35 Gy exhibiting chronic toxicity, with
reduced bone marrow recovery 1 year after treatment (8).
Most of the data concerning the risk of HT and bone
marrow irradiation have been collected from studies of anal
cancer (9) or cervical cancer (10, 11), in which the large
planning treatment volumes (PTVs) often abut or overlap
the pelvic bones (pelvis, sacrum, lumbar spine). The pelvic
bones, combined, containw50% of the body’s active bonemarrow. Doseevolume metrics such as the mean pelvic
bone dose and pelvic bone V10Gy and V20Gy (percentage of
volume receiving  xGy) have been linked to the risk of
grade 2 leukopenia and neutropenia (10), when the
external contour of the pelvic bony structures was used as a
surrogate for bone marrow irradiation. Intensity modulated
radiation therapy techniques (intensity modulated radiation
therapy [IMRT] and volumetric modulated arc therapy
[VMAT]) can be used in the treatment of these tumor sites
for improved pelvic bone marrow sparing. Reduced HT in
cervical cancer (12) and reductions in HT for anal cancer
(13) treated with IMRT and scanned proton therapy (14)
have been reported. These delivery techniques can also be
combined with functional imaging to identify active bone
marrow regions within the pelvis to guide dose optimiza-
tion (11, 15, 16). The dose to subsites of the pelvic bone
(eg, lumbosacral spine, which contains 25% of the bone
marrow) has also been identified as an important predictor
of HT (17), and preferential dose sparing to a subregion of
pelvic bone might be more easily achieved.
HT is also observed in patients undergoing chemo-
radiation therapy for thoracic malignancies (2, 18, 19).
Approximately 35% of the active bone marrow is found in
the thoracic vertebrae (VT) (20). A reduced proliferation of
irradiated bone marrow in the thoracic spine after only 2 Gy
has also been detected using FLT-PET imaging for lung
cancer patients undergoing chemoradiation therapy (21).
A recent study of 52 lung cancer patients treated with
3-dimensional (3D) conformal radiation therapy and IMRT
found the TV dose parameters (mean dose, V20Gy, andV30Gy)
were associated with the risk of grade3 leukopenia (22). A
study of 41 esophageal cancer patients investigated similar
doseevolume parameters (TVmean dose, V20Gy, and V10Gy)
to propose cutoff values to avoid the development of grade
3 leukopenia (23). The size and position of the target vol-
umes also means that the potential for dose sparing of the
bone marrow in the thorax might be greater than that for the
pelvis, especially if IMRT, VMAT, or proton therapy is used.
Although these techniques might improve the conformality
of the high-dose region, the distribution of low doses (5-
15 Gy) is very different with IMRTor VMAT compared with
3D conformal radiation therapy. Proton therapy plans have
demonstrated a reduction in bone V10Gy by 30% and 27%
compared with 3D50 and IMRT plans, respectively (24).
Also, reduced HT for lung cancer patients treated with pas-
sive scattering proton therapy has been reported (25).
Given the proximity and anatomic location of the
esophagus in relationship to the vertebral bodies and the
Volume 99  Number 3  2017 Proton therapy for reducing bone marrow toxicity 731technological capabilities of modern linear accelerators, the
potential for bone marrow sparing for individual patients
also merits further investigation.
Therefore, we compared the doseevolume metrics for
thoracic bone structures to identify differences in the dose
distribution for a representative group of patients with mid-
esophageal cancer from conformal, VMAT, and proton
therapy techniques. The potential for reoptimizing VMAT
plans to improve bone marrow sparing or selecting patients
for proton therapy is also illustrated by comparing the
dosimetric parameters for individual patients.Methods and Materials
The data from 21 patients who had undergone definitive
chemoradiation therapy for mid-esophageal cancer from the
SCOPE1 clinical trial previously used to model dose esca-
lation and proton treatment delivery were further investi-
gated (4, 5). These patients, with a mean PTV of 327 cm3
(range 140-591) had been randomly selected previously (4,
5) as a representative subset of the entire SCOPE1 trial
database, for which the mean PTV was 334 cm3.
The trial-derived GTVs were used for each patient, and
each GTV was extended along the esophagus manually by
2 cm cranially and caudally. The clinical target volume
(CTV50Gy) was created using an additional radial margin of
1 cm, and no elective nodal irradiation was given. Another
1-cm margin was added to generate the PTV50Gy, which
received a dose prescription of 50 Gy in 25 fractions for the
standard dose plans. For the plans with a SIB dose pre-
scription of 62.5 Gy in 25 fractions, the CTV62.5Gy was
considered identical to the GTV, and the PTV62.5Gy was
then generated using an isotropic margin of 0.5 cm to allow
for dose fall off from 62.5 to 50 Gy.
A surrogate for bone marrow (bone) was created by
outlining the TV (T1-T12 inclusive), sternum, scapulae,
ribs, and clavicles using the automatic thresholding tool in
Eclipse (Varian Medical Systems, Palo Alto, CA). A
separate volume for the body of the thoracic vertebrae T1 to
T12 was created (TV). The dose calculated from the 3D
conformal plan (3D50), typically of 4 fields (ante-
roposterior and lateraleoblique) was available and was
used to record the dose to the bone and TV.
Additional treatment plans were created retrospectively
in Eclipse using the VMAT technique and, for dose-
escalated plans, using VMAT and proton therapy. All arc
therapy plans consisted of 2 complete 360 arcs (clockwise
and counterclockwise) of 6 MV. Initially, 1 plan with the
same standard dose prescription used in the original treat-
ment plan (VMAT50) and a dose-escalated VMAT plan
(VMAT62.5) with a SIB dose prescription of 62.5 Gy in 25
fractions to the high-risk subregion within the PTV were
created (4).
A 3-field spot-scanning proton therapy plan with 70 to
250 MeV using single-field optimization (SFO62.5) was
createdwith the same SIB dose prescription using an anteriorand posterioreoblique beam arrangement to improve heart
and lung sparing (26). Additional field-specific proximal and
distal margins of 0.3 to 0.5 cmwere applied to the PTV50Gy to
account for a 3.5% range error (5). The same doseevolume
constraints for plan optimization, target coverage, and dose
to the organs at risk (heart, lung, spinal cord) were initially
applied to the VMAT and proton plans, and no explicit dose
constraints for bone marrow sparing were used initially. The
dose distributions obtained with these 4 plans are shown in
Figure 1.
Subsequently, a dose-escalated and bone marrow-sparing
VMATplanwas created for each patient to reduce the dose to
the bone marrow (VMAT62.5bm). Using all the thoracic
bone structures (T1-T12, sternum, scapulae, ribs, and clavi-
cles) as an optimization volume was deemed impractical.
Thus, the dose reduction was applied only to the TV volume
nonoverlapping with the PTV using a mean dose constraint
and additional doseevolume constraints in the 10- to 30-Gy
region for the TV substructure. The proton plans were not
reoptimized for bone marrow sparing, given the sharp dose
falloff around the target adjacent to the TV volume and the
already low dose to the other thoracic bone structures.
For all the plans, the bone mean dose, bone V20Gy, bone
V10Gy, TVmean dose, TV V20Gy, TVV10Gy, lung mean dose,
lung V20Gy, heart mean dose, and heart V30Gy dose metrics
were recorded. Tests for statistical significance were per-
formed in SPSS, version 20 (IBMCorp., Armonk, NY) using
the Wilcoxon signed rank test for pairwise comparisons of
the doseevolume metrics for the different irradiation tech-
niques. To better understand the parameters (eg, PTV, num-
ber of vertebrae irradiated [NV], percentage of TVoverlap)
that might affect the potential for bone marrow sparing when
reoptimizing the VMAT62.5 plans, the differences in the
doseevolume metrics achieved for SFO62.5 versus
VMAT62.5 and SFO62.5 versus VMAT62.5bm were
examined for the individual patients to assess the benefits of
proton therapy for improving bone marrow sparing. These
were tested using the Pearson correlation.Results
The dose distribution data were compared quantitatively for
all patients for each technique (Fig. 2; Table E1; available
online at www.redjournal.org). The 3D50 plans generated
the highest bone mean dose (median 12.1 Gy, interquartile
range [IQR] 10.1%-12.5%) and bone V20Gy (median
27.5%, IQR 23.2%-28.8%). No clinically significant dif-
ference (ie, <2 Gy in absolute dose or <5% in VxGy) was
found between the original VMAT50 and VMAT62.5 plans
for any of the dosimetric parameters, suggesting that dose
escalation with VMAT could be achieved without a clini-
cally significant increase in bone marrow irradiation for all
patients. Both original VMAT plans generated a slightly
greater median bone V10Gy (VMAT50 median 35.3%, IQR
30.1%-41.0% and VMAT62.5 median 37.9%, IQR 31.6%-
41.8%) than did the 3D50 plans (median bone V10Gy
Fig. 1. Dose distributions for a typical mid-esophageal
cancer patient illustrating (a) 3-dimensional conformal
plan (3D50), (b) standard-dose volumetric modulated arc
therapy (VMAT) plan (VMAT50), (c) dose-escalated
VMAT plan (VMAT62.5), and (d) dose-escalated spot-
scanning proton plan (SFO62.5). Bone outlined in orange,
planning treatment volume to 50 Gy (PTV50Gy) in yellow,
and PTV62.5Gy in red. The dose color wash is from 10 Gy
(blue) to 40 Gy (green) to 65 Gy (red). (A color version of
this figure is available at www.redjournal.org.)
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Z Z 2.172, PZ.030 compared with VMAT50). No
clinically significant difference was found in the TV mean
dose between the photon techniques, and differences in TV
V20Gy were modest between the 3D50 (median 51.5%, IQR
45.5%-57.0%) and VMAT plans (VMAT50 median 46.0%,
IQR 43.3%-54.4% and VMAT62.5 median 47.5%, IQR
44.5%-55.3%). The median TV V10Gy for this group of
patients was similar to that of the 3D50 plans (median54.3%, IQR 47.9%-58.5%), VMAT50 plans (median
50.7%, IQR 46.6%-57.5%), and VMAT62.5 plans (median
51.0%, IQR 47.7%-58.4%), although the VMAT62.5bm
plans showed a small reduction in TV V10Gy (median
45.5%, IQR 41.2%-51.1%). This was similar in magnitude
to the TV V10Gy sparing with the SFO62.5 plans (median
TV V10Gy 47.1%, IQR 42.5%-52.1%).
In contrast, SFO62.5 showed clinically significant
sparing (>2 Gy in absolute dose or >5% in VxGy) for many
bone volume parameters compared with the photon tech-
niques, notably for the bone mean dose (median 5.7 Gy,
IQR 4.9-6.5) and bone V10Gy (median 23.0%, IQR 20.0%-
26.0%). In contrast to the VMAT62.5 plans, the TV mean
dose was reduced by >3 Gy (median 17.6 Gy, IQR 15.0-
19.8) for the proton planning technique. These differences
in the SFO62.5 versus VMAT62.5 plans were also highly
statistically significant (Z Z 4.015; P<.001). However,
for the overall group of patients, the SFO62.5 plans had TV
V10Gy values (median 47.1%, IQR 42.5%-52.1%) similar to
those of the VMAT62.5bm plans, indicating that the
smaller TV and PTV overlap can also be beneficial for TV
sparing in the VMAT62.5bm plans. Nevertheless, the
minimum TV V10Gy value (19.5%) for patients with the
smallest TV overlap in the PTV was much smaller for the
proton plans than for the VMAT62.5bm plans (33.0%).
The doseevolume parameters for the heart and lung are
also shown in Figure 2. These indicated that dose escalation
can be achievedwith only a small increase in themean dose to
lung and that proton plans produce significant sparing of the
heart, lung, and bone marrow structures compared with
VMATand conformal techniques, as described previously (5).
Notwithstanding the overall trends observed, consider-
able variation was found in the bone marrow doseevolume
metrics for individual patients (Fig. 3). The correlation of
mean dose for bone and TV with factors such as the NV
irradiated, percentage of TV overlap in the PTV (median
overlap 7.0%, IQR 5.0%-10.5%), and PTV was also
examined. For both bone and TV, although a general trend
was seen toward a higher dose with a larger NV, this is not a
sufficiently unique value to clearly differentiate patients at
the greatest risk of higher bone marrow irradiation,
regardless of the technique used.
Variations in the bone mean dose (and bone V20Gy and
V10Gy; data not shown) with the different treatment tech-
niques appeared most clearly linked to the PTV. For the
bone mean dose, a general increase in dose with PTV was
seen for the 3D50, VMAT50, and VMAT62.5 plans. For 16
of 21 patients, the V10Gy dose was greater with the
VMAT50 plans than with the 3D50 plans owing to the
increased low-dose bath generated by the arc therapy
technique. Only the proton plans were able to reduce the
doseevolume metrics for all the patients compared with all
the 3D50 and VMAT plans, in particular, when the PTV
was >300 cm3.
The trend toward a greater TV mean dose (and TV
V20Gy and TV V10Gy; data not shown) with a larger overlap
was more pronounced for the proton plans. Thus, for this
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ability to spare the TV with an overlap greater than w8%.
The results when applying the TV doseevolume cutoff
values to predict the risk of grade 3 leukopenia proposed
by Lee et al (23) and Deek et al (22) are listed in Table 1,
including the number of patients (absolute and percentage
of group) exceeding the threshold values for each treatment
technique. The cutoff values proposed by Lee et al (23) and
Deek et al (22) are different, but the trends observed were
the same. The SFO62.5 and VMAT62.5bm plans showed
the lowest risk of HT, which was greatly reduced compared
with the 3D50, VMAT50, and standard VMAT62.5 plans.
When reoptimizing the VMAT plans to explicitly spare
the bone marrow, the PTV, percentage of overlap of the TV,
and proximity and overlap of the PTV with other organs at
risk (eg, heart, lung, and spinal cord) were critical. For 1
patient (with the greatest TVoverlap with the PTVat 13.7%)
and close proximity of the PTV to the spinal cord, better bone
marrow sparing with VMAT62.5bmwas impossible, without
exceeding the dose constraints for the other organs at risk.
The dose to the bones and TVwas compared for each patient
for SFO62.5 versus VMAT62.5 and SFO62.5 versus
VMAT62.5bm (Fig. 4). The SFO62.5 plans compared with
the original VMAT plans reduced the mean dose to the bones
by amedian of 4.5Gy (IQR 3.6-5.4; ZZ4.015;P<.001) or
a median of 3.1 Gy (IQR 2.6-3.6; PZ.002) compared with
the reoptimized VMAT62.5bm plans. The proton plans were
better at sparing the low-dose region, even comparedwith the
reoptimized VMAT plans, with a median 11.4% absolute
reduction of bone V10Gy (ZZ 3.92; P<.001). For patients
with a PTV >300 cm3, this reduction in the percentage of
V10Gy with protons was >7%.
The differences in the TV mean dose and TV V20Gy as a
function of the percentage of TVoverlap for SFO62.5 versus
VMAT62.5 and SFO62.5 versus VMAT62.5bm are also
shown in Figure 4. The median gain in the TV mean dose
with proton therapy versus the original VMAT62.5 plan was
4.6 Gy (IQR 2.9-6.4), which correlated with the percentage
of TV overlap (Pearson correlation, rZ0.726; nZ21;
P<.001). However, on reoptimization (VMAT62.5bm
plans), this difference in mean dose was a median of 0.6 Gy
(IQR 0.1-1.5; rZ0.230; nZ20; PZ.329). For the TV
V20Gy, SFO62.5 compared with VMAT62.5 gave an abso-
lute difference of 11.6% (IQR 5.9%-18.9%), with correlated
with the percentage of TV overlap (rZ0.796; nZ21;
P<.001). On reoptimization of the VMAT plans, the median
reduction with SFO62.5 became 0.2% (IQR 1.9% to
1.3%) and did not appear to correlate with either the per-
centage of TVoverlap (rZ0.125; nZ20; PZ.601) or PTV
(not shown).Fig. 2. Box plots comparing the doseevolume parameters for
3-dimensional conformal (3D50), volumetric modulated arc ther
escalated single-field optimization (SFO62.5), and VMAT62.5bm
the 21 patients.
=Discussion
Our data have shown that in a representative group of patients
with mid-esophageal cancer, bone marrow irradiation is
highly dependent on the radiation treatment technique. We
have demonstrated that using VMATor protons can result in a
reduction of the dose to bone and TVin the 20- to 30-Gy range
compared with the 3D conformal treatment plans used in the
SCOPE1 trial. Proton therapy plans offer the greatest potential
for reduced irradiation of all thoracic bone structures, espe-
cially for patients with a larger PTV (>300 cm3 in the present
study), and was especially useful in sparing the low-dose re-
gion atw10Gy,whichwas not possiblewith theVMATplans.
We have also demonstrated that significant TV sparing in
the 20- to 30-Gy dose region is possible by reoptimizing the
VMAT plans, even with dose escalation. Optimal treatment
plans (using either protons or photons) would be best ach-
ieved using multicriteria optimization methods to balance
dose sparing of the bonemarrowwith the dose constraints for
the heart, lungs, and spinal cord for each individual patient,
although this was outside the scope of the present study. The
use of patient-specific beam arrangements for the proton
therapy plans could also change the dose distribution in the
region of the TV. Thus, the conclusions from the present
study might not be applicable when using different beam
geometries for treatment. Furthermore, proton plan robust-
ness to respiratory and cardiacmotion should be analyzed for
different beam geometries, although this would require
detailed information on both the timescale of the spot de-
livery and of each patient’s breathing and cardiac motion.
Our threshold limit of 300 cm3 for the PTV for the greatest
potential benefit from proton therapy might also depend on
the CTV and PTV margins used and might not be directly
applicable to other target volume delineation protocols.
One of the limitations of the present study was the lack
of consensus in the doseevolume parameters to predict HT,
both in the organ-at-risk delineation and in the dos-
eevolume threshold. We used values from the published
data for thoracic tumors (non-small cell lung cancer and
esophageal cancer), and although the values for the mean
TV dose were similar (23.9-25.9 Gy), the values for TV
V20Gy varied much more (56.0%-70%).
Using the TV doses from Deek et al (22) as a threshold
to predict leukopenia resulted in a variation of 19% to 38%
for the 3D conformal plans, broadly in line with the 28%
rate of HT observed in the standard arm of the SCOPE1
trial (2). The predicted toxicity rates for the VMAT (10%-
29%) and SFO62.5 (0%-10%) plans were much lower.
However, the cutoff values from Lee et al (23) predicted a
much lower incidence of grade >3 leukopenia for allbone, thoracic vertebrae (TV), heart, and lung obtained fo
apy to 50 Gy (VMAT50), dose-escalated VMAT62.5, dose
(optimized for bone marrow sparing) treatment plans for
-
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Table 1 Patients predicted to be at risk of grade 3 leukopenia using threshold doseevolume metrics for thoracic vertebrae from Lee
et al (23) and Deek et al (22)
Grade 3 leukopenia cutoff
Treatment plan
3D50 VMAT50 VMAT62.5 SFO62.5 VMAT62.5bm
Lee TV mean <25.9 Gy 3 (14) 2 (10) 2 (10) 0 (0) 0 (0)
Lee TV V20Gy <70% 1 (5) 1 (5) 1 (5) 0 (0) 0 (0)
Lee TV V10Gy <77% 1 (5) 1 (5) 0 (0) 0 (0) 0 (0)
Deek TV mean <23.9 Gy 8 (38) 3 (14) 6 (29) 2 (10) 1 (5)
Deek TV V20Gy <56.0% 5 (24) 4 (19) 4 (19) 0 (0) 0 (0)
Deek TV V30Gy <52.1% 6 (29) 2 (10) 2 (10) 0 (0) 0 (0)
Abbreviations: 3D50 Z 3-dimensional conformal radiation therapy; bm Z bone marrow sparing (plan); SFO Z single-field optimization;
TV Z thoracic vertebrae; VxGy Z percentage of volume receiving  X Gy; VMAT Z volumetric modulated arc therapy.
Data presented as absolute number of patients and percentage of the 21 patients included in the present study.
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Fig. 4. A comparison of doseevolume metrics for individual patients for bone as a function of (a,b) planning treatment
volume (PTV) and (c,d) thoracic vertebrae (TV) as a function of the percentage of TV overlap. Solid circles indicate dif-
ferences in the dose-escalated single-field optimization (SFO62.5) and original dose-escalated volumetric modulated arc
therapy (VMAT62.5) plans; open diamonds, differences with the reoptimized bone marrow-sparing VMAT62.5bm plans.
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patients predicted to experience HT.
The study by Lee et al (23) and the present study had some
notable differences. Also, the characteristics of the patient
cohort included in the present study could have influenced the
risk of HT, such as different chemotherapy regimens and
different radiation therapy dose prescriptions and techniques.
The clinical data from Lee et al (23) described preoperative
esophageal cancer patients receiving 2 cycles of neoadjuvant
chemoradiation therapy (cisplatin and 5-FU) to a maximum
dose of 48 Gy. In contrast, the standard arm of the SCOPE1
trial prescribed 2 cycles of induction chemotherapy (cisplatin
and 5-FU) before another 2 cycles of concurrent chemo-
radiation therapy to 50 Gy. The PTV in the study by Lee et al
(23) was alsomuch larger (median 519 cm3, range 300-1426)
than in our study, possibly because of elective node irradia-
tion, which might also affect the dose distribution in the re-
gion of the TV.
The use of different chemotherapy agents could have a
significant effect on HT, and data from pelvic IMRTsuggest that use of cisplatin and 5-FU causes significantly
less HT than the use of mitomycin C (27). We would
anticipate similar effects for thoracic tumors; thus, not only
the chemotherapy agent, but also the timing and dosage of
the chemotherapy regimen could alter the dose tolerance of
the thoracic bone marrow.
The benefit of proton therapy and/or the reoptimization
of photon plans depends on whether irradiation of all the
bone in the thoracic region or just the body of the TV are
most important for HT. Evidence from FLT-PET imaging
has shown that the proportion and distribution of active
bone marrow in the thorax varies considerably with age and
gender (28). One limitation of our study was that we used
the external bone contour as a surrogate for active bone
marrow, although the distribution of the active marrow
might be very different for each patient and would influence
the active bone marrow-sparing possibilities for each indi-
vidual patient. The idea of a compensatory response in
nonirradiated bone has also been proposed (11), and
sparing a sufficient bone marrow reserve from even low
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should be used, especially for patients with a small absolute
bone volume or receiving intense concurrent chemotherapy
regimens. Future work would ideally require imaging of
active bone marrow for each patient, to identify the region
of active bone marrow to be spared and to select those
patients who would benefit sufficiently from reoptimized
photon plans or those requiring proton planning to reduce
their risk of acute HT.Conclusion
VMAT plans can reduce the thoracic bone marrow dose in
the 20- to 30-Gy range for patients with mid-esophageal
cancer but will irradiate a larger bone V10Gy than will
conformal plans. Reoptimized VMAT plans showed
improved sparing of the TV volume; however, only proton
plans showed significant sparing for the bone V10Gy and
bone mean dose, especially for patients with a larger PTV.References
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